Lung Cancer Study Uses the ANGLE Parsortix System

April 12, 2019

Lung Cancer Study: ANGLE Parsortix System, a world-leading liquid biopsy company, is pleased to announce that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using ANGLE’s Parsortix system, which may give advance warning of relapse in non small cell lung cancer (NSCLC).

Lung Cancer Study is being conducted by the Hellenic Oncology Research Group (“Hellenic”) lead by the Principal Investigators, Associate Professor Athanasios Kotsakis and Professor Vassilis Georgoulias of the IASO General Hospital in Athens, Greece and is investigating both ctDNA (circulating tumor DNA, fragments of dead cancer cells) and CTCs.  The CTC evaluation is being undertaken by the University of Athens lead by Professor Evi Lianidou.  Parsortix is the only CTC system being used in the study.

Lung cancer has the highest incidence and mortality rate of all cancers (World Cancer Factsheet 2018: 2.1 million new cancer cases and 1.8 million deaths per annum).  Even where the cancer is detected early, 45% of all NSCLC patients will suffer disease recurrence within 8 to 18 months of surgery.  Where the cancer is detected late, the situation is far worse.  Advance warning of potential cancer relapse in NSCLC has the potential to improve patient outcomes by allowing targeted treatment earlier than would otherwise happen. Solid tissue biopsies are impractical on the repeat basis needed for follow-up monitoring.  Where they are possible, the tissue biopsy is expensive, and carries significant risk: up to 24% cause serious complications and up to 1% result in death.

The Hellenic study involves 50 operable early stage NSCLC patients having liquid biopsy blood tests prior to surgery, one month after surgery and then every three to six months until relapse.  The study is scheduled to complete in December 2021.  CTCs harvested from patient blood using the Parsortix system will be analysed using qRT-PCR and FISH to identify tumor clonal evolution with the intention of identifying both predictors of relapse and indications of suitable treatment.

Prof Evi Lianidou, Head of the Molecular Diagnostics Laboratory focused on Liquid Biopsy, University of Athens, commented: “Following our successful work in head and neck cancer with ANGLE’s Parsortix system, we are delighted to have initiated this important longitudinal study in non small cell lung cancer (NSCLC).  There is a major unmet medical need in NSCLC to predict early relapse and identify targeted therapies for personalised care.  We are excited about the potential for analysis of CTCs harvested by the Parsortix system to make a real difference for these patients.”

ANGLE Founder and Chief Executive, Andrew Newland, commented: “This is another example of ANGLE’s product based leveraged R&D approach delivering key benefits with a major study, which is being developed, executed and funded by a leading customer.  The high incidence and mortality rates of lung cancer create a pressing need for repeat biopsies to allow personalised medicine and we hope that our Parsortix liquid biopsy system can play a key role in delivering this to the benefit of patients, opening new markets for ANGLE.”

SourceANGLE plc
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy